The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD
Open accessAbstract
Background: A study was undertaken to record exacerbations and health resource use in patients with COPD during 6 months of treatment with tiotropium, salmeterol, or matching placebos.Methods: Patients with COPD were enrolled in two 6-month randomised, placebo controlled, double blind, double dummy studies of tiotropium 18 µg once daily via HandiHaler or salmeterol 50 µg twice daily via a metered dose inhaler.The two trials were combined for analysis of heath outcomes consisting of exacerbations, health resource use, dyspnoea (assessed by the transitional dyspnoea index, TDI), health related quality of life (assessed by St George's Respiratory Questionnaire, SGRQ), and spirometry.Results: 1207 patients participated in the study (tiotropium 402, salmeterol 405, placebo 400).Compared with placebo, tiotropium but not salmeterol was associated with a significant delay in the time to onset of the first exacerbation.Fewer COPD exacerbations/patient year occurred in the tiotropium group (1.07) than in the placebo group (1.49, p<0.05); the salmeterol group (1.23 events/year) did not differ from placebo.The tiotropium group had 0.10 hospital admissions per patient year for COPD exacerbations compared with 0.17 for salmeterol and 0.15 for placebo (not statistically different).For all causes (respiratory and non-respiratory) tiotropium, but not salmeterol, was associated with fewer hospital admissions while both groups had fewer days in hospital than the placebo group.The number of days during which patients were unable to perform their usual daily activities was lowest in the tiotropium group (tiotropium 8.3 (0.8), salmeterol 11.1 (0.8), placebo 10.9 (0.8), p<0.05).SGRQ total score improved by 4.2 (0.7), 2.8 (0.7) and 1.5 (0.7) units during the 6 month trial for the tiotropium, salmeterol and placebo groups, respectively (p<0.01 tiotropium v placebo).Compared with placebo, TDI focal score improved in both the tiotropium group (1.1 (0.3) units, p<0.001) and the salmeterol group (0.7 (0.3) units, p<0.05).Evaluation of morning pre-dose FEV 1 , peak FEV 1 and mean FEV 1 (0-3 hours) showed that tiotropium was superior to salmeterol while both active drugs were more effective than placebo.Conclusions: Exacerbations of COPD and health resource usage were positively affected by daily treatment with tiotropium.With the exception of the number of hospital days associated with all causes, salmeterol twice daily resulted in no significant changes compared with placebo.Tiotropium also improved health related quality of life, dyspnoea, and lung function in patients with COPD. METHODS Study designTwo 6-month studies were performed to compare tiotropium 18 µg once daily delivered by the HandiHaler and salmeterol See end of article for authors' affiliations . . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
Analysis of Incomplete Multivariate Data
Schafer, J. L. (1997) · doi:10.1201/9781439821862 · Cited by 6,012
Analysis of Incomplete Multivariate Data
Booth, D. E. (2000) · Technometrics · doi:10.1080/00401706.2000.10486013 · Cited by 5,627
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Rahman, M. M., & Siddiqui, M. M. R. (2017) · Anwer Khan Modern Medical College Journal · doi:10.3329/akmmcj.v7i1.31596 · Cited by 3,106
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035
Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary Disease
ANTHONISEN, N. R., MANFREDA, J., WARREN, C. P. W., HERSHFIELD, E. S., HARDING, G. K. M., & NELSON, N. A. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-2-196 · Cited by 2,492
Standardization of Spirometry—1987 Update
(1987) · American Review of Respiratory Disease · doi:10.1164/ajrccm/136.5.1285 · Cited by 2,315
Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease
SEEMUNGAL, T. A. R., DONALDSON, G. C., PAUL, E. A., BESTALL, J. C., JEFFRIES, D. J., & WEDZICHA, J. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709032 · Cited by 2,312
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Cited by
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
Soler-Cataluna, J. J. (2005) · Thorax · doi:10.1136/thx.2005.040527 · Cited by 1,931
Azithromycin for prevention of exacerbations of COPD
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104623 · Cited by 1,226
Qaseem, A., Wilt, T. J., Weinberger, S. E., Hanania, N. A., Criner, G., van der Molen, T., Marciniuk, D. D., Denberg, T., Schünemann, H., Wedzicha, W., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-3-201108020-00008 · Cited by 1,087
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Franciosi, L. G., Barnes, P. J., Brusasco, V., Burge, P. S., Calverley, P. M. A., Celli, B. R., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00099306 · Cited by 858
Self-citationRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Calverley, P. M., Rabe, K. F., Goehring, U.-M., Kristiansen, S., Fabbri, L. M., & Martinez, F. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61255-1 · Cited by 829
Metadata
- Authors
- Brusasco, V
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2005-10-21
- Volume
- 61
- Issue
- 1
- Pages
- 91-91
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W1981197711
- Cited by
- 431
- References
- 21
- FWCI
- 41.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. https://app.cochat.ai/papers/10.1136/thx.2005.brusascolett
- The paper
- Brusasco, V. (2005). Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. https://doi.org/10.1136/thx.2005.brusascolett
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.